Table 2.

Risk of incident atrial fibrillation in young adults with SLD

Subgroup	Number	Number of events	Follow-up duration (p-y)	Incidence rate (per 1,000 p-y)	Crude HR (95% CI)	Adjusted HR (95% CI)
						Model 1*	Model 2*
Non-SLD	4,603,095	14,772	47,427,013	0.31	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
All SLD	1,772,615	11,620	18,387,460	0.63	2.02 (1.97 –2.07)	1.49 (1.45 –1.53)	1.14 (1.10– 1.18)
MASLD	1,448,817	9,014	15,032,918	0.60	1.92 (1.87–1.97)	1.41 (1.37–1.45)	1.09 (1.05–1.31)
MetALD	239,830	1,834	2,486,934	0.74	2.36 (2.24–2.47)	1.73 (1.64–1.81)	1.29 (1.22–1.36)
ALD	83,968	772	867,609	0.89	2.85 (2.65–3.06)	2.08 (1.93–2.24)	1.52 (1.41–1.65)

* Model 1 adjusted by age and sex; Model 2 adjusted by age, sex, low income status, smoking, regular exercise, total cholesterol, fasting blood glucose level, systolic blood pressure, estimated glomerular filtration rate, and body mass index

ALD, alcohol-associated liver disease; CI, confidence interval; ; HR, hazard ratio; MASLD, metabolic dysfunction-associated steatotic liver disease; MetALD, metabolic dysfunction and alcohol-related liver disease; p-y, person-years; SLD, steatotic liver disease